What is the future of ribavirin therapy for hepatitis C?

Antiviral Research

Volumn 104, Issue 1, 2014, Pages 34-39

  Koh, Christopher ^a   Liang, T Jake ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Antiviral therapy; Chronic hepatitis C; Direct acting antivirals; Hepatitis C virus; Ribavirin

Indexed keywords

ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRUS AGENT; RIBAVIRIN; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; GENOTYPE; HEALTH CARE QUALITY; HEPATITIS C; HUMAN; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; DIRECT-ACTING ANTIVIRALS; HEPATITIS C VIRUS; RIBAVIRIN;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; RIBAVIRIN;

EID: 84893819990     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.01.005     Document Type: Note

References (68)

1. B.R. Bacon, S.C. Gordon, and E. Lawitz et al. Boceprevir for previously treated chronic HCV genotype 1 infection N. Engl. J. Med. 364 2011 1207 1217
2. Y. Benhamou, N.H. Afdhal, and D.R. Nelson et al. A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naive patients with chronic hepatitis C: ViSER1 results Hepatology (Baltimore, Md.) 50 2009 717 726
3. A.M. Di Bisceglie, M. Shindo, and T.L. Fong et al. A pilot study of ribavirin therapy for chronic hepatitis C Hepatology (Baltimore, Md.) 16 1992 649 654
4. S. Brillanti, J. Garson, and M. Foli et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C Gastroenterology 107 1994 812 817
5. V.E. Buckwold Implications of finding synergic in vitro drug-drug interactions between interferon-alpha and ribavirin for the treatment of hepatitis C virus J. Antimicrob. Chemother. 53 2004 413 414 (Pubitemid 38380235)
6. L. Chemello, L. Cavalletto, E. Bernardinello, M. Guido, P. Pontisso, and A. Alberti The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C J. Hepatol. 23 Suppl 2 1995 8 12 (Pubitemid 26048737)
7. S. Chevaliez, R. Brillet, E. Lazaro, C. Hezode, and J.M. Pawlotsky Analysis of ribavirin mutagenicity in human hepatitis C virus infection J. Virol. 81 2007 7732 7741 (Pubitemid 47047859)
8. R.T. Chung, M. Gale Jr., S.J. Polyak, S.M. Lemon, T.J. Liang, and J.H. Hoofnagle Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop Hepatology (Baltimore, Md.) 47 2008 306 320 (Pubitemid 351171068)
9. A.M. Di Bisceglie, H.S. Conjeevaram, and M.W. Fried et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial Ann. Intern. Med. 123 1995 897 903
10. J. Dietz, S.E. Schelhorn, and D. Fitting et al. Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients J. Virol. 87 2013 6172 6181
11. G. Dusheiko, J. Main, and H. Thomas et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study J. Hepatol. 25 1996 591 598 (Pubitemid 26373872)
12. EASL Clinical Practice Guidelines Management of hepatitis C virus infection J. Hepatol. 55 2011 245 264
13. G. Everson, K.D. Sims, and M. Rodriguez-Torres et al. Interim analysis of an interferon (IFN)- and ribavirin (RBV)- free regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 in treatment-naive, hepatitis C Virus genotype 1-infected patients J. Hepatol. 58 2013 S567 S577
14. G. Everson, K.D. Sims, and P.J. Thuluvath et al. Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naive patients with chronic HCV genotype 1 infection Hepatology (Baltimore, Md.) 58 2013 (LB-1)
15. J.J. Feld, G.A. Lutchman, and T. Heller et al. Ribavirin improves early responses to peginterferon through improved interferon signaling Gastroenterology 139 154-62 2010 e4
16. E.J. Gane, S.K. Roberts, and C.A. Stedman et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 2010 1467 1475
17. E.J. Gane, C.A. Stedman, and R.H. Hyland et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C N. Engl. J. Med. 368 2013 34 44
18. M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C: an update Hepatology (Baltimore, Md.) 49 2009 1335 1374
19. M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, and L.B. Seeff An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology (Baltimore, Md.) 54 2011 1433 1444
20. C.B. Hall, E.E. Walsh, J.F. Hruska, R.F. Betts, and W.J. Hall Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults JAMA 249 1983 2666 2670 (Pubitemid 13089433)
21. C. Hezode, N. Forestier, and G. Dusheiko et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N. Engl. J. Med. 360 2009 1839 1850
22. S.B. Ho, B. Aqel, and E. Dieperink et al. U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to- treat" HCV genotype 1 patients Dig. Dis. Sci. 56 2011 880 888
23. W.P. Hofmann, A. Polta, and E. Herrmann et al. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy Gastroenterology 132 2007 921 930 (Pubitemid 46440857)
24. J.W. Huggins, C.M. Hsiang, and T.M. Cosgriff et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome J. Infect. Dis. 164 1991 1119 1127
25. N. Izumi, M. Lataillade, and K. Chayama et al. First Report of Peginterferon Lambda/Ribavirin in Combination With Either Daclatasvir or Asunaprevir in HCV Genotype 1 Japanese Subjects: Early Sustained Virologic Response (SVR4) Results from the D-LITE Japanese Substudy Hepatology (Baltimore, Md.) 56 2012 234
26. I.M. Jacobson, R.S. Brown Jr., and J. McCone et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1 Hepatology (Baltimore, Md.) 46 2007 982 990 (Pubitemid 350144762)
27. I.M. Jacobson, J.G. McHutchison, and G. Dusheiko et al. Telaprevir for previously untreated chronic hepatitis C virus infection N. Engl. J. Med. 364 2011 2405 2416
28. I.M. Jacobson, M. Sulkowski, and E. Gane et al. VX-222, telaprevir and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C: results of the ZENITH study interferon-free regimen Hepatology (Baltimore, Md.) 56 2012 308a-a
29. I.M. Jacobson, S.C. Gordon, and K.V. Kowdley et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N. Engl. J. Med. 368 2013 1867 1877
30. N. Kamar, L. Rostaing, and F. Abravanel et al. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection Gastroenterology 139 2010 1612 1618
31. G. Koren, S. King, S. Knowles, and E. Phillips Ribavirin in the treatment of SARS: A new trick for an old drug? CMAJ 168 2003 1289 1292 (Pubitemid 36609908)
32. K.V. Kowdley, and F. Poordad et al. Safety and Efficacy of Interferon-Free Regimens of ABT-450/r, ABT-267, ABT-333 +/- Ribavirin in Patients with Chronic HCV GT1 Infection: Results from the AVIATOR Study J. Hepatol. 58 2013 S2
33. E. Lawitz, and E.J. Gane Sofosbuvir for previously untreated chronic hepatitis C infection N. Engl. J. Med. 369 2013 678 679
34. E. Lawitz, F. Poordad, and K.V. Kowdley et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1 J. Hepatol. 59 2013 18 23
35. E. Lawitz, J.M. Vierling, and A. Murillo High efficacy and safety of the all-oral combination regimen, MK-5172/MK-8742 +/- RBV for 12 weeks in HCV genotype 1 infected patients: the C-WORTHY study Hepatology (Baltimore, Md.) 58 2013 244A 245A
36. E. Lawitz, F.F. Poordad, P.S. Pang, R.H. Hyland, X. Ding, H. Mo, W.T. Symonds, J.G. McHutchison, and F.E. Membreno Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial Lancet. 2013 pii: S0140-6736(13)62121-2
37. J.H. Lee, M. von Wagner, W.K. Roth, G. Teuber, C. Sarrazin, and S. Zeuzem Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus J. Hepatol. 29 1998 29 35 (Pubitemid 28307980)
38. T.J. Liang, and M.G. Ghany Current and future therapies for hepatitis C virus infection N. Engl. J. Med. 368 2013 1907 1917
39. C.C. Lin, L. Philips, C. Xu, and L.T. Yeh Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers J. Clin. Pharmacol. 44 2004 265 275 (Pubitemid 38236158)
40. K. Lindahl, L. Stahle, A. Bruchfeld, and R. Schvarcz High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C Hepatology (Baltimore, Md.) 41 2005 275 279 (Pubitemid 40165370)
41. A.S. Lok, D.F. Gardiner, and E. Lawitz et al. Preliminary study of two antiviral agents for hepatitis C genotype 1 N. Engl. J. Med. 366 2012 216 224
42. A.S. Lok, D.F. Gardiner, and C. Hezode et al. Sustained Virological Response in Chronic HCV Genotype (GT) 1-Infected Null Responders With Combination of Daclatasvir (DCV;NS5A Inhibitor) and Asunaprevir (ASV; NS3 Inhibitor With or Without Peginterferon Alfa-2a/Ribavirin (PEG/RBV) Hepatology (Baltimore, Md.) 56 2012 230-a 231-a
43. P. Marcellin, R.G. Gish, and N. Gitlin et al. Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients J. Hepatol. 52 2010 32 38
44. J.B. McCormick, I.J. King, and P.A. Webb et al. Lassa fever. Effective therapy with ribavirin N. Engl. J. Med. 314 1986 20 26 (Pubitemid 16183064)
45. J.G. McHutchison, G.T. Everson, and S.C. Gordon et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N. Engl. J. Med. 360 2009 1827 1838
46. D.F. Meyer, H. Tobias, and A.D. Min et al. Retreatment of patients nonresponsive to pegylated interferon and ribavirin with daily high-dose consensus interferon Hepatitis Res. Treat. 2010 2010 537827
47. A.J. Muir, M.L. Shiffman, and A. Zaman et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection Hepatology (Baltimore, Md.) 52 2010 822 832
48. A. Osinusi, E.G. Meissner, and Y.J. Lee et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial JAMA 310 2013 804 811
49. J.L. Patterson, and R. Fernandez-Larsson Molecular mechanisms of action of ribavirin Rev. Infect. Dis. 12 1990 1139 1146
50. F. Poordad, E. Lawitz, and M.L. Shiffman et al. Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C Hepatology (Baltimore, Md.) 52 2010 1208 1215
51. F. Poordad, J. McCone Jr., and B.R. Bacon et al. Boceprevir for untreated chronic HCV genotype 1 infection N. Engl. J. Med. 364 2011 1195 1206
52. F. Poordad, E. Lawitz, and K.V. Kowdley et al. Exploratory study of oral combination antiviral therapy for hepatitis C N. Engl. J. Med. 368 2013 45 53
53. Rebetol ® [package insert]. In: Merck, (Ed.), Whitehouse Station, NJ: Merck, 2013.
54. O. Reichard, J. Andersson, R. Schvarcz, and O. Weiland Ribavirin treatment for chronic hepatitis C Lancet 337 1991 1058 1061
55. Y. Rotman, M. Noureddin, and J.J. Feld et al. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C Gut. 63 1 2014 161 169
56. R.W. Sidwell, J.H. Huffman, G.P. Khare, L.B. Allen, J.T. Witkowski, and R.K. Robins Broad-spectrum antiviral activity of Virazole: 1-beta-D- ribofuranosyl-1,2,4-triazole-3-carboxamide Science (New York, NY) 177 1972 705 706
57. D.B. Strader, T. Wright, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C Hepatology (Baltimore, Md.) 39 2004 1147 1171 (Pubitemid 38428955)
58. M. Sulkowski, D.F. Gardiner, and M. Rodriguez-Torres et al. Sustained virological response with daclatasvir plus sofosbuvir +/- ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC) J. Hepatol. 58 2013 S567 S577
59. M. Sulkowski, F. Poordad, and M. Manns et al. Anemia during treatment with peginterferon alfa-2B/ribavirin with Or without boceprevir is associated with higher SVR rates: analysis of previously untreated and previous-treatment- failure patients J. Hepatol. 54 2011 S194 S195
60. M. Sulkowski, R.K. Reddy, and N. Afdhal et al. Anemia had no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimen in the advance and illuminate phase 3 studies J. Hepatol. 54 2011 S195
61. Y. Suzuki, K. Ikeda, and F. Suzuki et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options J. Hepatol. 58 2013 655 662
62. E. Thomas, J.J. Feld, Q. Li, Z. Hu, M.W. Fried, and T.J. Liang Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models Hepatology (Baltimore, Md.) 53 2011 32 41
63. M.J. Tong, S.J. Hwang, and M. Lefkowitz et al. Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin J. Gastroenterol. Hepatol. 9 1994 587 591 (Pubitemid 24364609)
64. J.M. Vierling, M. Lataillade, and E. Gane Sustained virologic response (SVR12) in HCV genotype 1 patients receiving peginterferon lambda in combination with ribavirin and either daclatasvir or asunaprevir: interim results from the D-LITE study Hepatology (Baltimore, Md.) 56 2012
65. J.Z. Wu, C.C. Lin, and Z. Hong Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design J. Antimicrob. Chemother. 52 2003 543 546 (Pubitemid 37258410)
66. Z.M. Younossi, M. Stepanova, and L. Henry et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C) J. Hepatol. 2013
67. S. Zeuzem, G. Dusheiko, and R. Salupere Sofosbuvir + ribavirin for 12 or 24 wrrks for patients with HCV genotype 2 or 3: the VALENCE trial Hepatology (Baltimore, Md.) 58 2013 733A 734A
68. S. Zeuzem, V. Soriano, and T. Asselah et al. Faldaprevir and deleobuvir for HCV genotype 1 infection N. Engl. J. Med. 369 2013 630 639